Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

Table 5 HbA1c and body weight

	Baseline (Visit 2)	∆ from baseline	∆ from end of period 1	p-value*
HbA_1c in %, mean ± SD
Sequence A	8.17 ± 0.73	−1.17 ± 1.05	0.21 ± 0.58	<0.0001
Sequence B	8.13 ± 0.72	−1.17 ± 0.93	0.09 ± 0.63	<0.0001
p-value**		0.97	0.10
Body weight in kg, mean ± SD
Sequence A	90.1 ± 15.8	0.40 ± 3.31	0.67 ± 2.51	0.70
Sequence B	91.0 ± 15.13	0.51 ± 3.34	0.73 ± 3.10	0.68
p-value**		0.77	0.86

Legend: * Paired t-test was applied for comparison of treatments within sequence; ** Unpaired t-test was applied for comparison of treatments in periods; Sequence A: starting with insulin glargine and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin glargine

ISSN: 1477-7525